Cited by 966Bone Metabolism and DiseasesBone health and osteoporosis researchBone and Dental Protein Studies

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Poole, Kenneth E. S., Van Bezooijen, Rutger L., Loveridge, Nigel, Hamersma, Herman, Papapoulos, Socrates E., Löwik, Clemens W., Reeve, Jonathan·2005·The FASEB Journal

DOI 10.1096/fj.05-4221fje

Open this paper in CoChat — free account

Abstract

Osteocytes are the most abundant cells in bone and are ideally located to influence bone turnover through their syncytial relationship with surface bone cells. Osteocyte‐derived signals have remained largely enigmatic, but it was recently reported that human osteocytes secrete sclerostin, an inhibitor of bone formation. Absent sclerostin protein results in the high bone mass clinical disorder sclerosteosis. Here we report that within adult iliac bone, newly embedded osteocytes were negative for sclerostin staining but became positive at or after primary mineralization. The majority of mature osteocytes in mineralized cortical and cancellous bone was positive for sclerostin with diffuse staining along dendrites in the osteocyte canaliculi. These findings provide for the first time in vivo evidence to support the concept that osteocytes secrete sclerostin after they become embedded in a mineralized matrix to limit further bone formation by osteoblasts. Sclerostin did not appear to influence the formation of osteocytes. We propose that sclerostin production by osteocytes may regulate the linear extent of formation and the induction or maintenance of a lining cell phenotype on bone surfaces. In doing so, sclerostin may act as a key inhibitory signal governing skeletal microarchitecture.

Integrity signals

Registry

Crossref · 10.1096/fj.05-4221fje

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Bone Resorption by Osteoclasts
Teitelbaum, S. L. (2000) · Science · doi:10.1126/science.289.5484.1504 · Cited by 3,962
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G., Sutherland, M. K., Geoghegan, J. C., Yu, C., Hayes, T., Skonier, J. E., Shpektor, D., Jonas, M., Kovacevich, B. R., Staehling‐Hampton, K., et al. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,114
Bone Dysplasia Sclerosteosis Results from Loss of the SOST Gene Product, a Novel Cystine Knot–Containing Protein
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Self-citation
Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist
van Bezooijen, R. L., Roelen, B. A. J., Visser, A., van der Wee-Pals, L. J. A., de Wilt, E., Karperien, M., Hamersma, H. A., Papapoulos, S. E., ten Dijke, P., & Löwik, C. W. G. M. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031454 · Cited by 893
Self-citation
Loss of Osteocyte Integrity in Association with Microdamage and Bone Remodeling After Fatigue In Vivo
Verborgt, O., Gibson, G. J., & Schaffler, M. B. (2000) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2000.15.1.60 · Cited by 731
Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells
Dobnig, H., & Turner, R. T. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628403 · Cited by 614
Periosteum: biology, regulation, and response to osteoporosis therapies
Allen, M. R., Hock, J. M., & Burr, D. B. (2004) · Bone · doi:10.1016/j.bone.2004.07.014 · Cited by 449
The Death of Osteocytes via Apoptosis Accompanies Estrogen Withdrawal in Human Bone
Tomkinson, A., REEVE, J., Shaw, R. W., & Noble, B. (1997) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.82.9.4200 · Cited by 417
Self-citation

Show all 34 references

Research works printed but not linked: 2

Warmington K., 2004, Sclerostin antagonism in adult rodents, via monoclonal antibody mediated blockade, increases bone mineral density and implicates sclerostin as a key regulator of bone mass during adulthood (Abstract), J. Back Musculoskeletal. Rehabil., 19, S56
10.1210/jc.82.9.3128 · DOI

Sorted by citations

Items 901–966 of 966

Pharmacological Treatment of Osteoporosis
Malouf, J., Magallares, B., & Güerri‐Fernández, R. (2015) · InTech eBooks · doi:10.5772/59469
Targeting pro-survival cell signaling pathways in multiple myeloma
Spaan, I. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/1172
Faculty Opinions recommendation of Osteoporosis: now and the future.
Elisaf, M., & Rizos, C. V. (2013) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.717991070.793473318
Peer Review #1 of "Loading history changes the morphology and compressive force-induced expression of receptor activator of nuclear factor kappa B ligand/osteoprotegerin in MLO-Y4 osteocytes (v0.1)"
(2020) · PeerJ · doi:10.7287/peerj.10244v0.1/reviews/1
Osteocytes
Bonewald, L. F. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375098-3.50009-3
Sclerostin and Wnt Antagonists: Implications for Osteoporosis Therapies
Ke, H. Z., Li, X., Suen, P. K., Qin, L., & Holdsworth, G. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11547-8
Myeloma Bone Disease
Simic, M. K., & McDonald, M. M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11258-9
Osteoblasts in Human Skeletal Diseases
Findlay, D. M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11174-2
Les lois de Wolff. Conséquences cliniques 2e partie
Bert, M. (2018) · Actualités Odonto-Stomatologiques · doi:10.1051/aos/2018023
References
(2015) · Elsevier eBooks · doi:10.1016/b978-0-12-416678-3.00059-8
Wnt Signaling in Bone
Johnson, M. L., & Recker, R. R. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-375098-3.50018-4
Peer Review #2 of "Loading history changes the morphology and compressive force-induced expression of receptor activator of nuclear factor kappa B ligand/osteoprotegerin in MLO-Y4 osteocytes (v0.1)"
(2020) · PeerJ · doi:10.7287/peerj.10244v0.1/reviews/2
Bone Research Society 2015
(2015) · doi:10.3389/978-2-88919-659-3
Therapieverfahren
(2018) · Elsevier eBooks · doi:10.1016/b978-3-437-22102-6.00005-6
Unloading and Disuse Osteopenia
Pajevic, P. D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.11217-6
Circulating Sclerostin in Bone Sclerosing Disorders
van Lierop, A. H., & Papapoulos, S. E. (2017) · Biomarkers in disease · doi:10.1007/978-94-007-7693-7_39
Self-citation
Peer Review #2 of "Loading history changes the morphology and compressive force-induced expression of receptor activator of nuclear factor kappa B ligand/osteoprotegerin in MLO-Y4 osteocytes (v0.2)"
(2020) · PeerJ · doi:10.7287/peerj.10244v0.2/reviews/2
Peer Review #1 of "Loading history changes the morphology and compressive force-induced expression of receptor activator of nuclear factor kappa B ligand/osteoprotegerin in MLO-Y4 osteocytes (v0.2)"
(2020) · PeerJ · doi:10.7287/peerj.10244v0.2/reviews/1
Präklinische Zell- und Tiermodelle zur Untersuchung der Auswirkungen des Parathormons auf den Zahnhalteapparat
Marnet, K., Schiffmaier, J., & Herrmann, M. (2022) · Osteologie/Osteology · doi:10.1055/a-1830-9347
WITHDRAWN: Wnt signaling pathway in the development of atherosclerosis: Sclerostin as a new surrogate marker of global vascular calcification?
Kocełak, P., Puzianowska‐Kuźnicka, M., Olszanecka‐Glinianowicz, M., & Chudek, J. T. (2022) · Journal of Molecular and Cellular Cardiology Plus · doi:10.1016/j.jmccpl.2022.100010 · Cited by 1
Retracted
Role of sclrostin (SOST) to predisposing for osteoporosis in β- thalassemia major patients
Al-Saray, Z. A., Al-Maamori, J. A. I., & Al-Ta'ai, A. M. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns6.12388
The role of pre-receptor glucocorticoid metabolism in chronic inflammatory disease-associated muscle atrophy
Webster, J. M. (2023) · doi:10.26481/dis.20230329jw
Effects of Anti-Sclerostin Antibody Release from Porous Microparticles on Bone Resorption Inhibition of Osteoblasts
Watanabe, H., Nakagawa, Y., Ikoma, T., Hattori, S., Minowa, T., & Hanagata, N. (2023) · Drug Delivery Letters · doi:10.2174/2210303113666230316124601
Association of genetic variants located at the Adenylate Cyclase 5 (ADCY5) and Parathyroid Hormone 1 Receptor (PTH1R) genes with type 2 Diabetes Mellitus in Bangladeshi populationPreprint
Nawar, N., Alam, B., Faisal, A.-R. M., Khan, S. M., Hosen, M. I., & Shekhar, H. U. (2023) · Research Square · doi:10.21203/rs.3.rs-2883067/v1
Vitamin D activity in osteoblasts and osteocytes
Anderson, P. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-91386-7.00030-1
Parathyroid Gland and Bone Therapies
Quarde, A. (2023) · doi:10.1002/9781119863564.ch5
Bone equilibria and disruptions
van Bosse, H. J. P. (2024) · Journal of the Pediatric Orthopaedic Society of North America · doi:10.1016/j.jposna.2024.100059
Osteoporosis treatment: Bone-forming agents
Langdahl, B. L., Mäkinen, V.-N., & Sølling, A. S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00053-4
Mechanical Analysis of Romosozumab's Effects on Bone Strength in a Rat Posterolateral Lumbar Fusion Model
Mukaihata, T., Inage, K., Shiga, Y., Kim, G., Tajiri, I., Toshi, N., Suzuki, M., Inoue, M., Ohtori, S., & Orita, S. (2025) · Cureus · doi:10.7759/cureus.79802
Underestimated Roles of Osteocytes in Medication-Related Osteonecrosis of the Jaw
Xu, C., & Wu, Y. (2025) · Regenerative medicine and dentistry. · doi:10.53941/rmd.2025.100003
Nano-Scale Peri-Lacunar Bone Formation and Implications for the Modulation of Whole Bone QualityPreprint
Ford, S., Tiedemann, K., Shapiro, R., Komarova, S. V., Jähn, K., & Zimmermann, E. A. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5277249
Fractures incidence and its association on mortality in multiple myeloma patients: a nationwide cohort study (CAREMM-2105 study)
Ha, J., Choi, S., Park, S., Moon, S., Han, J., Lee, J., Baek, K., Han, S., & Min, C. (2025) · Scientific Reports · doi:10.1038/s41598-025-09811-4
Bone turnover markers
Cavalier, E., Jørgensen, N. R., Makris, K., Bhattoa, H. P., Lombardi, G., Pikner, R., & Vasikaran, S. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13825-6.00232-6
Depletion of mmu-miR-185 enhances osteocyte connectivity and suppresses bone fragility through the interaction between ARL8B and RAB5A
Cui, Y., Hai, B., Han, X., Leng, H., He, D., Lu, Y., Wang, H., Xu, J., & Zhao, H. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04612-y
Cortical Bone Loss and Fragility in a 2-Month Triple Transgenic Mouse Model of Alzheimer’s Disease
Storlino, G., Posa, F., Dell'Endice, T. S., Piccolo, F., Colaianni, G., Cassano, T., Grano, M., & Mori, G. (2025) · Cells · doi:10.3390/cells14221816
Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition
Þórólfsdóttir, R. B., Sveinbjörnsson, G., Eldjárn, G. H., Aegisdottir, H. M., Styrkársdóttir, U., Grétarsdóttir, S., Steinthórsdóttir, V., Tragante, V., Oddsson, Á., Stefánsdóttir, L., et al. (2025) · Human Molecular Genetics · doi:10.1093/hmg/ddaf177
Role of soft tissue and bone interactions in the developmental integration and modularity of the skull in neural crest‐specific gap junction alpha‐1 knockout mice
Moore, A. C., Tourigny, M. S. G., Quinonez, D., Barr, K., Grol, M. W., & Willmore, K. E. (2025) · The Anatomical Record · doi:10.1002/ar.70115
Additional file 1 of Parathyroid hormone (1–34) retards the lumbar facet joint degeneration and activates Wnt/β-catenin signaling pathway in ovariectomized rats
Gou, Y., Li, H., Sun, X., Chen, D., & Tian, F. (2024) · Figshare · doi:10.6084/m9.figshare.26043653
Regulation of the expression of Sclerostin in periodontal fibroblasts
Gruber, M. (2011) · University of Vienna · doi:10.25365/thesis.14876
Additional file 2 of Parathyroid hormone (1–34) retards the lumbar facet joint degeneration and activates Wnt/β-catenin signaling pathway in ovariectomized rats
Gou, Y., Li, H., Sun, X., Chen, D., & Tian, F. (2024) · Figshare · doi:10.6084/m9.figshare.26043806
Additional file 3 of Parathyroid hormone (1–34) retards the lumbar facet joint degeneration and activates Wnt/β-catenin signaling pathway in ovariectomized rats
Gou, Y., Li, H., Sun, X., Chen, D., & Tian, F. (2024) · Figshare · doi:10.6084/m9.figshare.26733897
Effects of Endocrine Disruptors on the Molecular Regulation of Bone Metabolism: Wnt/β-Catenin Signaling Pathway
Deren, K. A. Y. A., & Şemsi, R. (2026) · FUTURE BIOCHEMISTRY AND BIOSCIENCE · doi:10.48086/asd0089
Combination Treatment with Sclerostin and Dkk1 Antibodies Synergizes with Tibial Loading to Stimulate Bone Formation in Aged MicePreprint
Lawson, L. Y., Chermside‐Scabbo, C. J., Brodt, M. D., Migotsky, N., Shuster, J. T., Buettmann, E. G., & Silva, M. J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.23.707532
Current outlook on the use of monoclonal antibody therapies for osteoporosis
Almohaya, M. S., Almehthel, M. S., & Kendler, D. L. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2641051 · Cited by 1
Osteocyte biology
Kitase, Y., Prideaux, M., Bellido, T., Pajevic, P. D., & Bonewald, L. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-13683-2.00043-8
Ostéoblastes et environnement physico-chimique : effets du contenu minéral matriciel et des micro-vibrations
Perrier, A. (2010) · doi:10.70675/75dcee23za4f6z414dzb338z2f66308a0517
Associations cellules souches mésenchymateuses et céramiques pour l'ingénierie tissulaire osseuse : intérêt du milieu cellulaire et de l'environnement tridimensionnel sur la différenciation ostéoblastique
Cordonnier, T. (2010) · theses.fr (ABES) · doi:10.70675/004f5db1z573dz4db8zae29z8311b99fd503
Bone union and strength effect of Romosozumab: An imaging and mechanical study using a rat posterolateral lumbar fusion modelPreprint
Mukaihata, T., Inage, K., Shiga, Y., Kim, G., Tajiri, I., Eguchi, Y., Suzuki-Narita, M., Tsuchiya, R., Otagiri, T., Hishiya, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1993343/v1
Mécanismes épigénétiques associés à la progression et à la chimiorésistance des sarcomes osseux
Jacques, C. (2016) · theses.fr (ABES) · doi:10.70675/6683be42z2eb1z41f0z9807z56236b95837b
Utilisation de cellules souches pulpaires combinées à une matrice de collagène pour la réparation osseuse cranio-faciale
Collignon, A.-M. (2018) · doi:10.70675/43f7dbb8z6829z48aez8a82zfdf5c50398a0
Msx2 et Sost/Sclérostine : deux modulateurs du développement et de la réparation de la dentine
Amri, N. (2018) · doi:10.70675/5876ce6fzc330z4d40zbe12zabd5a1bbe644
Etude des effets anti-inflammatoires et anti-cancéreux de nouvelles molécules agrosourcées à motif pyridazinone
Moniot, A. (2020) · theses.fr (ABES) · doi:10.70675/9be60ae3z24c2z427fzbfcbzf7a9c8fa1f39
Impact du variant rare pVal667Met de LRP5 sur le phénotype osseux et oculaire chez l'homme et dans un modèle expérimental
Fabre, S. (2021) · theses.fr (ABES) · doi:10.70675/7f44a234ze685z4b1dz8621z3f4b191eacef
Etude du rôle du récepteur LPA1 dans l'ostéogénèse au cours de la croissance du squelette : implication dans l'acquisition de masse osseuse
Alioli, A. C. (2020) · theses.fr (ABES) · doi:10.70675/91ed89a7zfc2fz442fz8da8zad0726b68cdd
Circulating Wnt Signaling Inhibitors and Osteoprotegerin in Women with Newly Diagnosed Overt Thyroid Dysfunction
Miteva, M. Z., Orbetzova, M. M., Nonchev, B., Davcheva, D. M., & Gigov, K. (2026) · Metabolites · doi:10.3390/metabo16050308
The potential role of the gut microbiota in the development of autoantibodies associated with Spondyloarthritis: a narrative review
Elsaghir, A., Wadan, A. S., & Witte, T. (2026) · BMC Immunology · doi:10.1186/s12865-026-00855-3
Bone anabolic effects of tibial loading in combination with dual sclerostin and Dkk1 antibodies in aged mice
Lawson, L. Y., Chermside‐Scabbo, C. J., Brodt, M. D., Migotsky, N., Shuster, J. T., Buettmann, E. G., & Silva, M. J. (2026) · JBMR Plus · doi:10.1093/jbmrpl/ziag106
Exercise-responsive crosstalk within local muscle-bone units in osteosarcopenia: from mechanotransduction to secretome signalling
Guan, Z., Fu, X., Zhang, P., Luo, Z., Wu, H., Liu, Q., & Xu, Y. (2026) · Frontiers in Physiology · doi:10.3389/fphys.2026.1923562
Characterising skull pathologies in the Sost -deficient mouse for preclinical evaluation of sclerosteosis treatments
Dreyer, T. J., Gouldie, E., Keen, J. A. C., Salmon, P., Holdsworth, G., Pitsillides, A. A., & Roberts, S. J. (2026) · Disease Models & Mechanisms · doi:10.1242/dmm.052839
Optimizing Bone Remodeling: A Control-Theoretic Approach to Model the Combination Therapy of Parathyroid Hormone and Denosumab
Sreekumar, A., & Chakravarty, K. (2026) · Journal of Environmental Accounting and Management · doi:10.5890/jeam.2027.03.003
Effectiveness and limitations of anti-sclerostin therapy in osteogenesis imperfecta: A systematic review
Wu, Z., den Haan, S., Perek, F., Nijhuis, W. H., Weinans, H., Sakkers, R. J. B., Spaans, A. J., & Warmink, K. (2026) · Bone · doi:10.1016/j.bone.2026.118085
Dual Effects of β‐ TrCP2 Deletion in Bone Homeostasis: Suppression of Osteoclastogenesis and Enhancement of Osteoblast Activity
Kim, W. J., Han, S., Ka, H. I., Lee, S. Y., Kim, J., Joo, H., Soh, S., Oh, G., Yoo, K. H., Han, S. H., et al. (2026) · Arthritis & Rheumatology · doi:10.1002/art.70351
Treatment sequence and treatment goals following osteoporotic vertebral compression fractures
Beall, D. P., Webb, J. R., Beall, O. A., Johnson, J. C., Kaufmann, A., Beall, S. E., Elghzali, A., Rahimi, M., & Khan, S. A. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33042-1.00004-1
Single-cell and bulk transcriptomic characterization of the osteosarcoma microenvironment reveals lineage-specific programs and inflammatory differences associated with metastasis
Zhou, Z., & Li, Z. (2026) · Frontiers in Genetics · doi:10.3389/fgene.2026.1927885
BindingDB Entry 50014860: Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis.
BindingDB (2023) · UC San Diego · doi:10.7270/q2q81hxk
The effects of stroke on the skeleton
Poole, K. E. S. (2006) · OpenGrey (Institut de l'Information Scientifique et Technique) · doi:10.17863/cam.16645
Self-citation

Authors: Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J.
Affiliations: University of Cambridge (GB)
Department of Endocrinology and Metabolic Diseases Leiden University Medical Centre Leiden Netherlands
South Africa
Leiden University (NL)
ORCID: Poole, Kenneth E. S.
Loveridge, Nigel
Hamersma, Herman
Papapoulos, Socrates E.
Löwik, Clemens W.
Reeve, Jonathan
Venue: The FASEB Journal
Publisher: Wiley
Published: 2005-08-25
Volume: 19
Issue: 13
Pages: 1842-1844
ISSN: 0892-6638 (ISSN-L)
1530-6860
DOI: 10.1096/fj.05-4221fje
OpenAlex: W1970864109
Cited by: 965
References: 34
Citations by year: 2026: 21 · 2025: 28 · 2024: 32 · 2023: 39 · 2022: 38 · 2021: 45 · 2020: 74 · 2019: 63 · 2018: 55 · 2017: 53 · 2016: 66 · 2015: 67 · 2014: 55 · 2013: 62 · 2012: 63
FWCI: 10.29
Type: journal article
Language: en
Open access: closed
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor)
Locations: The FASEB Journal (publishedVersion)
PubMed (publishedVersion)
Funders: Medical Research Council
National Osteoporosis Society
European Commission (LSHM‐CT‐2003‐503020)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Bone and Dental Protein Studies
Keywords: sclerostin, osteocytes, bone formation inhibition, sclerosteosis, osteoblasts, bone mineralization, bone lining cells, bone turnover
MeSH terms: Aged, Alkaline Phosphatase, Antibodies, Monoclonal, Biopsy, Bone and Bones, Bone Development, Bone Diseases, Developmental, Bone Resorption, Cell Differentiation, Coloring Agents, Female, Genetic Markers, Humans, Image Processing, Computer-Assisted, Immunohistochemistry, Male, Microscopy, Fluorescence, Middle Aged, Models, Biological, Osteoblasts, Osteocytes, Osteogenesis, RNA, Messenger, Time Factors, Tolonium Chloride, Signal Transduction, Bone Remodeling, Bone Morphogenetic Proteins, Adaptor Proteins, Signal Transducing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks